The plasmid DNA manufacturing market involves the production of plasmids that act as vectors for genetic material within living cells. Plasmids are circular, self-replicating DNA molecules that are distinct from a cell's chromosomal DNA. They are commonly used as DNA vectors to introduce genetic material into target host cells. Plasmid DNA manufacturing finds applications in gene therapy, DNA vaccination, biologics production, and stem cell-based treatment. Growing demand for plasmid DNA in genetic engineering, clinical research, and development of novel therapeutics is driving the plasmid DNA manufacturing market. The introduction of advanced production technologies like fed-batch fermentation, DNA amplification, and plasmid extraction has increased plasmid yields and reduced overall manufacturing cost.
Global plasmid DNA manufacturing market is estimated to be valued at US$ 735.67 million in 2022 and is expected to exhibit a CAGR of 22.5% during the forecast period (2022-2030).
Key Takeaways
Key players operating in the plasmid DNA manufacturing market include Northrop Grumman Corporation, BAE Systems, Lockheed Martin Corporation. These key players are focusing on facility expansion, production scale-up, and consolidating their market presence through strategic collaborations.
The Plasmid DNA Manufacturing Market Trends from the biopharmaceutical industry for clinical research and vaccine development is propelling the plasmid DNA manufacturing market. Plasmid DNA finds widespread adoption in gene therapies, DNA vaccines, and recombinant protein production, fueling significant market growth.
Global expansion of gene therapies and DNA vaccine production is another factor contributing to the rise of the plasmid DNA manufacturing industry. Leading market players are increasing their international footprint to capitalize on opportunities across different geographic regions.
Get More Insights on- Plasmid DNA Manufacturing Market
